Statin Therapy and Cardiovascular Risk Reduction

Dementia Risk and Cognitive Function

The American College of Cardiology and American Heart Association recommend that fear of cognitive decline should not prevent the use of statins in patients requiring cardiovascular risk reduction, as statins do not adversely affect cognition or increase dementia risk 1, 2
Multiple high-quality guidelines from the American Diabetes Association, American College of Cardiology/American Heart Association, and U.S. Preventive Services Task Force have found no evidence that statins cause cognitive impairment or increase dementia risk 1, 2
In patients with diabetes and high cardiovascular risk, control of cholesterol with statins has been associated with reduced risk of incident dementia 5

The American College of Cardiology recommends that the reduction in cardiovascular disease risk from statins substantially exceeds any potential cognitive concerns, particularly in high-risk populations 2
In patients taking high-intensity statins for secondary prevention or primary prevention with ≥7.5% 10-year ASCVD risk, the cardiovascular benefit far outweighs the minimal risk of diabetes or any other adverse effect 2
For patients on moderate-intensity statins, the risk reduction benefits outweigh potential harms 2

Rhabdomyolysis is a rare but serious side effect of statins, occurring in 0.01 excess cases per 100 patients 2
Routine creatine kinase monitoring is not recommended, but baseline measurements should be obtained in patients at increased risk, and checked if muscle symptoms develop 2
Baseline alanine transaminase should be measured before initiation of statin therapy, and routine monitoring is not recommended unless symptoms of hepatotoxicity develop 2

The American College of Cardiology recommends a high-intensity statin (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) for patients <75 years to reduce ASCVD events more than moderate-intensity therapy 2
For patients >75 years, moderate-intensity statin therapy is recommended for safety reasons, including increased comorbidities and potential side effects 2
Obtain fasting lipid panel before starting and 4-12 weeks after initiating therapy, and consider decreasing statin dose if LDL-C <40 mg/dL on two consecutive measurements 2